Tuck:
I don't know anything about transdermal delivery.
Nada.
Nichts.
Squat.
But, they're for real and I've been interested (tangents, tangents, tangents!) for some time........
BACKGROUND
The following is a brief summary of the background of each nominee for
election as a Director of the Company:
ROBERT J. PALMISANO has served as the Company's Chief Executive Officer and
President and as a Director since April 9, 2001. From 1997 to 2000 he was Chief
Executive Officer and Director of Summit Technology, Inc. From 1984 to January
1997, Mr. Palmisano was employed at Bausch and Lomb, Inc., where he served from
1988 to 1996 as Senior Vice President and President of the Eyewear Division.
From January 1997 to April 1997, Mr. Palmisano was a private consultant. He
holds a B.A. from Providence College.
JOHN L. ZABRISKIE, PH.D., has served as a Director of the Company since
2000 and as Chairman of the Board of Directors since March 22, 2001. From 1997
to 2000, he was Chairman, President and Chief Executive Officer of NEN Life
Science Products, which was sold to Perkin Elmer. In 1994, Dr. Zabriskie became
Chairman, President and Chief Executive Officer of Upjohn; he was responsible
for Upjohn's merger with the Swedish pharmaceutical company Pharmacia, and
became C.E.O. of the merged company. Before his appointment at Upjohn, he spent
nearly 30 years with Merck & Company, rising to Executive Vice President and
President of Merck Manufacturing Division. He is a member of the Board of
Directors of the following publicly traded companies: Biomira Inc. (since 1998);
Cubist Pharmaceuticals, Inc. (since 1998); and Kellogg Company (since 1995). Dr.
Zabriskie received a B.S. in chemistry from Dartmouth College and a Ph.D. in
organic chemistry from the University of Rochester.
PETER G. MARTIN has served as a Director of the Company since 1995. Since
1990 Mr. Martin has been an independent investment banker and venture
capitalist. Prior to 1990 he was a commercial banker. Mr. Martin was initially
elected to the Board of Directors as the designee of David Russell, who
privately purchased 1 million shares of the Company's Common Stock in 1995. Mr.
Russell is no longer entitled to designate a Director of the Company. Mr. Martin
received a B.A. and J.D. from Fordham University and an M.B.A. from Columbia
University.
MICHAEL A. DAVIS, M.D., SC.D., has served as a Director of the Company
since 1997 and has provided medical and pharmaceutical consulting services to
the Company since 1991. Since 1980, Dr. Davis has been Professor of Radiology
and Nuclear Medicine and Director of the Division of Radiologic Research at
University of Massachusetts Medical School. From 1982 to 1997 Dr. Davis was
Adjunct Professor of Surgery at Tufts University School of Veterinary Medicine.
4
<PAGE>
Since 1986, he has been Affiliate Professor of Biomedical Engineering at
Worcester Polytechnic Institute. He is also a director of EZ EM, Inc., a public
company engaged in supplying oral radiographic contrast media, as well as
medical devices. In addition, from February to November 1999 he was President
and Chief Executive Officer of Amerimmune Pharmaceuticals, Inc., formerly known
as Versailles Capital Corporation, a public company, and its wholly owned
subsidiary, Amerimmune Inc., which is engaged in developing drugs relating to
the immune system. Since February 1999, Dr. Davis has been a director of both
Amerimmune Pharmaceuticals, Inc. and Amerimmune Inc.. Dr. Davis received a B.S.
and M.S. from Worcester Polytechnic Institute, an S.M. and Sc.D. from the
Harvard School of Public Health, an M.B.A. from Northeastern University and an
M.D. from the University of Massachusetts Medical School.
ROBERT J. DELUCCIA has served as a Director of the Company since 2000. Mr.
DeLuccia is currently a director of IBEX Technologies, Inc., a publicly traded
biotechnology company developing enzymes for a variety of therapeutic
applications. From 1998 through 1999 Mr. DeLuccia was President and Chief
Executive Officer and a director of Immunomedics, Inc. Immunomedics is a
publicly traded biotechnology company focused on diagnostic and therapeutic
products for the detection and treatment of cancer and infectious diseases. From
1994 through 1997, Mr. DeLuccia was President of Sterling Winthrop
Pharmaceuticals and Senior Vice President of Sanofi Winthrop, Inc. Sanofi
Winthrop Inc. was then the U.S. subsidiary of Sanofi (now Sanofi-Synthelabo),
based in Paris, France. Sanofi Winthrop focused on a wide range of
cardiovascular, thrombosis, rheumatoid arthritis, analgesics and oncology
products as well as a full line of parenteral products in a proprietary drug
delivery system. From 1984 through 1994, Mr. DeLuccia was also with Sterling
Drug as a Vice President in a variety of marketing roles prior to the company's
sale by Eastman Kodak to Sanofi. From 1974 through 1981 Mr. DeLuccia held sales,
marketing and general management positions at Pfizer, Inc. Mr. DeLuccia holds
both an M.B.A. and a B.S. in marketing from Iona College.
PAUL S. ECHENBERG has served as a Director of the Company since 2000. Since
1997 he has been the President and Chief Executive Officer of Schroders &
Associates Canada, Inc. and a director of Schroder Ventures Limited. These firms
provide merchant banking advisory services to a number of Canadian buy-out
funds. He is a director of the following companies: EZ EM, Inc., a supplier of
oral radiographic contrast media and medical devices; Cedara Software Inc.;
Benvest Capital Inc., a merchant bank that he founded; and Shirmax Fashions Ltd.
From 1989 through 1997, Mr. Echenberg was President of Eckvest Equity, Inc., a
private merchant bank providing consulting and personal investment services.
From 1970 to 1989, he was President and Chief Executive Officer of Twinpak,
Inc., a manufacturer of plastic packaging, and from 1982 to 1989 was Executive
Vice President of CB Pak, Inc., a publicly traded plastic, glass and packaging
company. Mr. Echenberg received a B.Sc. from McGill University and an M.B.A.
from Harvard Business School.
5
<PAGE>
EXECUTIVE OFFICERS
The executive officers of the Company, their ages and their positions with
the Company are as follows:
NAME AGE POSITION WITH COMPANY
- -------------------------------------------------------------------------------
Robert J. Palmisano.....56 Chief Executive Officer, President and Director
Bernard R. Patriacca....57 Vice President, Chief Financial Officer, Treasurer
and Secretary
Paul J. Schechter......61 Vice President, Drug Development & Regulatory
Affairs
Melvin A. Snyder........58 Vice President, Market Development
The following is a brief summary of the backgrounds of Mr. Patriacca, Dr.
Schechter and Mr. Snyder. The background of the Company's other executive
officer, Mr. Palmisano, is summarized above.
BERNARD R. PATRIACCA, C.P.A., the Company's Vice President, Chief Financial
Officer, Treasurer and Secretary since April 23, 2001, was from 1997 to 2001
Vice President and Controller of Summit Technology, Inc. From 1994 to 1997, he
served as Vice President of Errands Etc., Inc., a privately held homeowners'
personal service company. From 1991 to 1994, Mr. Patriacca held senior financial
management positions at several privately held consumer services companies. From
1973 to 1991, he was employed in various capacities at Dunkin Donuts, Inc.,
including Chief Financial Officer and Director. Mr. Patriacca received a B.S.
and an M.B.A. from Northeastern University.
PAUL J. SCHECHTER, M.D., PH.D., the Company's Vice President, Drug
Development and Regulatory Affairs since May 1998, was from 1973 to 1990 with
Merrell Dow Research Institute, where he attained the position of Vice President
for Clinical Research. He went on to become Vice President of Fujisawa
Pharmaceutical Company from 1990 to 1993. Most recently he served as Senior Vice
President, Drug Development with Hybridon, Inc. from 1993 to 1997. Dr. Schechter
holds an M.D. and Ph.D. in Pharmacology from the University of Chicago and a
B.S. from Columbia University, College of Pharmacy.
MELVIN A. SNYDER, the Company's Vice President for Market Development since
October 20, 2000, was from June 1999 until October 2000 consulting director of
business development of the Company. From 1998 until 1999 he was Vice President
of Marketing and Business Development at Immunomedics, and between 1995 and 1998
he was a consultant to several pharmaceutical companies including Immunomedics.
Between 1975 and 1995, he was President of ProClinica Inc., a marketing
communications and licensing-support company. Mr. Snyder holds a bachelor's
degree from Lehigh University. |
